Nuclear Medicine & Radiation Therapy

Nibal Saad

Publications

• Research Article
  Utilization of Radioimmunotherapy (RIT) and Hematopoietic Stem Cell Transplantation (HSCT) in B-cell Non-Hodgkin�¢����s Lymphoma (NHL): 10 Year Experience of a Single Community Cancer Center
  Author(s): Nibal Saad, Kleanthe Kolizeras, Susan M Szpunar and Ayad Al-KatibNibal Saad, Kleanthe Kolizeras, Susan M Szpunar and Ayad Al-Katib
  
  After Yttrium (Y90) Ibritumomab tiuxetan (Zevalin) and Iodine (131I) tositumomab (Bexxar) were approved by the FDA, the improved response of B-cell NHL to this novel RIT makes it a promising alternative to more aggressive treatment like HSCT. In this study, we describe the experience of a single community-based cancer with RIT and HSCT in patients with B-cell NHL in terms of response, survival and toxicity. Retrospectively, we reviewed 75 patients with B cell NHL who were treated with either RIT (N=50) or HSCT (N=25) between 2003 and 2013. Choice of treatment modality, i.e. RIT vs. HSCT was based on discretion of treating Oncologist taking into consideration patient’s age, performance status, comorbidity and preferences. RIT-treated patients were older. HSCT was more likely to be used in aggressive lymphoma and as a consolidation of primary therap.. Read More»
  DOI: 10.4172/2155-9619.1000331

  Abstract PDF